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Abstract A tumor stimulates the remodeling of its
microenvironment in order to control and accelerate its
own growth and to initiate metastases. To create metas-
tases the tumor cells must first acquire the ability to
detach from the main tumor and to adhere to, invade, and
degrade the adjacent extracellular matrix. The cells must
then be able to enter the lumen of the vessels where they
home the distant tissues and organs by forming secondary
tumors. The acquisition of this phenotype is related to the
phenomenon of epithelial-to-mesenchymal transition. On
the molecular level, this process is typified by a change in
the expression of epithelial markers and by the enhance-
ment of the expression of mesenchymal markers like
vimentin that are responsible for cell migration and
invasion. Metallothioneins have been shown to help
protect against apoptosis. The expression of MT by tumor
cells plays an important and complex role not only
because of its pro-proliferative, anti-apoptotic activity,
but also because it inhibits the immune response. The
aim of the present study was to evaluate the immunore-
activity of vimentin and MT in the salivary gland
adenocarcinoma and its stroma in order to observe the
phenomenon of stromal remodeling. The tissue samples of
salivary gland adenocarcinomas and their stromas and the
palatine tonsils which constituted the reference group were
obtained during routine surgical procedures. The immu-
noreactivity of vimentin, metalothionein, CD56, CD57
antigens was evaluated by the immunohistochemistry
method in 30 tissue samples of parotid adenocarcinoma.
The patient’s consent was obtained in each case. A
statistically significantly higher level of MT immunoreac-
tivity was observed in the adenocarcinoma tissue slides
than in either the stromal slides or the reference slides
while no differences in MT immunoreactivity were
detected when the stroma and reference tissue slides were
compared. A statistically significantly higher vimentin
immunoreactivity level was identified in the tumor
microenvironment tissue slides than in the tumor tissue
slides, and a statistically significantly higher level of
vimentin immunoreactivity was identified in the tumor
microenvironment slides than in the slides of the reference
tissue, while no differences were identified between the
adenocarcinoma tissue slides and the reference slides with
respect to vimentin immunoreactivity. A statistically
significantly higher number of CD56- and CD57-
expressing cells were identified in the reference tissue
slides than in either the adenocarcinoma or stromal slides.
In conclusion, the stroma of salivary gland adenocarcino-
ma in this study has been characterized by remodeling.
The remodeling is represented by the expression of both
vimentin and MT and by a deficit of CD57- and CD58-
expressing cell infiltration. This situation would seem to
be the result of immune tolerance for the tumor
developing within the tumor microenvironment. Further-
more, the presence of MT and vimentin immunoreactivity
in the fibroblasts of the tumor stroma may constitute a
marker of active tissue remodeling.
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A tumor stimulatesthe remodelingofits microenvironmentin
order to control and accelerate its own growth and to initiate
metastases. The tumor thus induces angiogenesis and forms
new capillaries of enhanced permeability, changes the
structure of the extracellular matrix and the function of the
cells (including the immune system cells), and activates the
homing of the tumor microenvironment by the immune cells
(which with their altered function become responsible for the
chronic inflammation that accompanies tumor development
as compared with a non-healing wound) [1–5]. The tumor
microenvironment is composed of cells, extracellular matrix,
and proteins. Within the microenvironment, the endothelial
cells, tumor-associated macrophages, and carcinoma-
associated fibroblasts have been identified as the most
important for promoting tumor progression [1–5].
To create metastases the tumor cells must first acquire
the ability to detach from the main tumor and to adhere to,
invade, and degrade the adjacent extracellular matrix. The
cells must then be able to enter the lumen of the vessels
where they home the distant tissues and organs by forming
secondary tumors. The acquisition of this phenotype is
related to the phenomenon of epithelial-to-mesenchymal
transition (EMT) [6–8]. On the molecular level, this process
is typified by a change in the expression of epithelial
markers and the enhancement of the expression of
mesenchymal markers responsible for cell migration and
invasion. EMT is a physiological process observed during
embryological development and the remodeling of tissue
during wound healing and chronic inflammation [9]. The
metastasizing cells demonstrate features similar to cells
undergoing EMT, and EMT is thought to participate in
tumor progression. EMT is defined as the phenomenon
which occurs when the cell loses its stable, polarized, non-
migrational abilities and transforms into a mesenchymal
cell with fibroblastic, migrational features. As the cells lose
their polarization, a change in both the cell-to-cell and cell-
to-extra-cellular matrix adhesion occurs, leading to higher
cell mobility [10]. During EMT, epithelial cells progres-
sively redistribute and decrease the expression of the
proteins typical for the apex and basis of the cell, such as
cell connection proteins which include E-cadherine. In turn,
mesenchymal proteins such as vimentin and N-cadherine
are re-expressed by the cells. These changes lead to the
disappearance of the connections between the cells and as a
result the cells acquire the mobility needed to invade the
tissues [11].The mesenchymal phenotype can also be
reversed by blocking vimentin expression; this results in
the re-expression of epithelial features and a decrease in
tumor aggressiveness [12]. Since vimentin has never been
studied in salivary gland adenocarcinomas we aimed to
determine its immunoreactivity in these tumors and their
microenvironments in order to observe the remodeling of
the tumor microenvironment. Vimentin is one of the
markers for identifying activated fibroblasts or the myofi-
broblasts of the tumor microenvironment. These are also
called carcinoma-associated fibroblasts (CAF) as the
number of these cells increases significantly in various
malignant tumors. They constitute an important component
of the tumor microenvironment and participate in the
tumor’s development [13]. Myofibroblasts have many
features in common with both smooth muscle cells and
fibroblasts and induce the growth and differentiation of
cells during embryogenesis, wound healing, and other
physiological processes related to tissue remodeling [13].
The most common precursor cells for myofibroblasts are
fibroblasts, but the smooth muscles of the vessels,
pericytes, precursor bone marrow cells, and even cancer
cells can transdifferentiate into myofibroblasts. PDGF
secreted by the tumor stimulates fibroblast proliferation;
TGF-β secreted by macrophages chemoattracts fibroblasts
in lower concentration, while in higher concentration it
induces the transdifferentiation into myofibroblasts [13].
Myofibroblasts appear shortly before tumor invasion and
degrade the basal membrane and extracellular matrix by
secreting serine proteases and matrix metalloproteinases.
The stromal fibroblasts in oral squamous cell carcinomas
have been demonstrated to be associated in a significant
way with carcinomas but not with pre-malignant lesions
[14]. Myofibroblasts express insulin-like and hepatocyte
growth factors which induce and stimulate the survival and
migration of cells as well as the expression of pro-
angiogenic and pro-inflammatory factors. Myofibroblasts
stimulate not only their own migration to the tumor, but
also the survival, proliferation, and invasion of tumor cells
and the process of angiogenesis. Together these factors
increase the ability of the tumor to grow and disseminate
[15–17]. CAF are routinely identified by such markers as:
alpha-smooth muscle actin (alpha-SMA), vimentin,
S100A4 protein/fibroblast specific protein-1 (FSP1), and
type-I collagen [18].
Tumor microenvironment remodeling may also be char-
acterized by changes in MT expression. Metallothioneins
(MTs) have been shown to play a protective role against
apoptosis [19] and may also be important for the prolifer-
ation and differentiation of cells [20, 21]. MT expression in
the cytoplasm of the cell has been found to be involved in
protecting against cytotoxicity while the nuclear expression
of MT is involved in protecting against genotoxicity.
Genotoxicity involves the acquisition of the malignant
phenotype by the cell; this is associated with the specific
mutations that play key roles in carcinogenesis [20–23].
Cytotoxicity, by contrast, is involved in the interactions of
immune system cells with cancer cells. The role played by
the expression of MT by tumor cells is important and
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apoptotic activity of this protein, but also because it inhibits
the immune response [24–27].
The tumor controls the immune response in the tumor
microenvironment and modifies the antitumor immune
response. There are two populations of lymphocytes or NKTs
(natural killer-like Tcells), CD56-expressing cells and CD57-
expressing cells. These cells are typified by an immunoreg-
ulatory role [28, 29]. CD56-positive T lymphocytes demon-
strate an effector function of cytotoxic T cells [30], while
CD57-positive T lymphocytes demonstrate an immunoregu-
latory role for T cytotoxic lymphocytes. The expression of
CD57antigenisalsorelatedtoTEM (effector memory Tcells),
especially a significant number of TEMRA (expressing
CD45RA CD3
+CD8
+CD57+CD28- and high perforin ex-
pression) [31, 32]. NKT TEM cells are typified by an
immediate effector function [32]. As the immunohistochem-
istrymethodallows us to identify only oneantigen at a time, in
the current study we were not able to identify the type of cell
precisely. We have therefore determined only the immunore-
activity levels of CD56 and CD57 antigens in salivary gland
adenocarcinomas and their microenvironments.
Materials and Methods
The Group of Patients
Patients with Salivary Adenocarcinoma
All the tissue samples were derived from patients whose
salivary gland tumors were surgically removed in the
Otolaryngology Department of the Jagiellonian University.
The patient’s consent was obtained in each case. Addition-
ally, approval for the research program was granted from
the Ethical Committee of the Jagiellonian University in
Krakow: KBET/90/B/2005. We recruited 30 patients to our
study from those who had undergone the surgery between
January 2000 and December 2008. All the tumors originat-
ed from parotid glands; tumors originating from other
smaller salivary glands were excluded from the present
study. In each case parotidectomy along with lymphade-
nectomy was performed. The tumors were removed in
healthy surgical margins. The presence of lymph node
metastases in these removed lymph nodes was then
evaluated. All the patients were treated surgically, and none
of the patients enrolled in the study had been pre-treated
using chemo- or radiotherapy. Additionally, we have
compared the immunoreactivity of analyzed antigens in
both primary and recurrent tumors, but were unable to
identify any significant associations.
All the tissue samples were histopathologically verified.
Pathological analysis using the classical hematoxylin and
eosin staining techniques after fixation in a formalin of the
surgically removed material was performed in the Pathol-
ogy Department of the Jagiellonian University by two
experienced pathologists (R.T. and A.L.) working indepen-
dently. The tissue material was then fixed in the solution of
10% formalin, rinsed, dehydrated, and transferred through a
progressively increasing concentration of ethanol (from
50% to absolute alcohol); it was passed through xylens I, II,
and III as well as molten paraffin wax. Lastly, the tissue
blocks were sectioned and placed onto 3–4 μm slides. The
process was mainly automated, but both the paraffin
embedding and the sectioning of the tissue samples into
3–4μm slides were performed manually.
The clinical characteristics of the subjects are presented
in Tables 1 and 2.
Reference Group
As a reference group we chose palatine tonsils that had
been removed due to recurrent tonsillitis. In these tissue
samples we evaluated the epithelium lining the tonsils, and
not the lymphoid tissue (Table 2).
Table 1 The clinical characteristics of the patients with salivary
adenocarcinomas
The number of patients 30
M
a 13
W
a 17
Age range (average) 12–79 (55.9)
Tumor stage
b
I–II 25
III–IV 5
The presence of lymph node metastases
N0 25
N+ 5
Tumor size
T1–T2 29
T3–T4 1
Tumor grade
G1 1
G2 22
G3 7
Histological types of tumors
Adenocarcinoma 16
Adenocarcinoma acinocellulare 14
Tumors
Primary 25
Recurrence 5
aM men, W women
bTumor stage was evaluated according to TNM classification 6th
edition, 2002
MT and Vimentin Role in Tumor Microenvironment Remodeling 107Immunohistochemical Analysis
In the present study we aimed to analyze the immunoreac-
tivity of various antigens in parotid adenocarcinoma and its
stroma; we were also interested in the distribution of the
antigen immunoreactivity among the whole tissue of the
tumor, including the tumor stroma. For this reason we chose
the immunohistochemistry method for the present study.
This is the only method that shows the actual architecture of
the dialogue between the tumor and its stroma.
From every tumor 3–4 tissue samples were taken
(depending on the tumor size; if, for instance, the tumor
was 1 cm in diameter, then it was subject to further analysis).
Every tissue sample was embedded in paraffin and formed
into a tissue block which was then cut into tissue slides. All
the tissue slides were further histopathologically verified and
fortheadditionalanalysisthemostrepresentativeslideswere
selected for immunohistochemistry (for the analysis of the
tumor samples and the stromal samples and in order to assess
the tumor-stroma interaction).
Two observers, working independently and having no
knowledge of the clinicopathological data, reviewed the
immunohistochemical expression of MT, vimentin, CD56-
and CD57-positive cells. Immunohistochemical analysis
was performed in the Pathology Department of the
Jagiellonian University. Five-micrometer slides from each
case were deparaffinized, rehydrated, and rinsed in distilled
water. Endogenous peroxidase activity was blocked by
8 min of incubation in 3% H2O2 at room temperature. The
slides were then rinsed and immersed in boiling citrate
buffer (pH 6.0) in a microwave oven with three changes of
buffer for 5 min each. Immunohistochemistry was per-
formed in each case applying the Envision method using
Dako Autostainer. The samples were stained automatically.
The immunohistochemical staining was based on antigen-
antibody reaction. The microscopy was performed using an
Axio Zeiss microscope and the tissue slides were evaluated
under both 20x and 40x magnification.
The following antibodies were applied: CD56, CD57
(Novocastra in dilution 1:50), Vimentin (DAKO, Denmark,
in dilution 1:50), and Metallothionein (ABCAM, in dilution
1:25) for 10 min at room temperature. Sections were
counterstained with hematoxylin and mounted in glycergel.
As a positive control, a tonsil specimen was taken for
Metallothionein. All stainings were performed with the same
procedure only the primary antibody was omitted as a
negative control. Metallothionein expression was evaluated
in entire slides in the area of the tumor and in the stroma, as
Table 2 The characterization of the reference group
Palatine tonsils
The number of patients 20
M
a 9
W
a 11
Age range average 16–57 30.41
M
a 20–53 33.37
W
a 16–57 27.7
aM men, W women
Fig. 1 The immunoreactivity of CD56 (A) and CD57 (B) antigens in adenocarcinoma and its stroma, representing the cytoplasmic pattern of
staining. Moderately differentiated adenocarcinoma; sample magnification 20x
108 M. Dutsch-Wicherek et al.follows: 0—no reactivity; +1—weak, when observed any
cytoplasmic staining pattern (alsogranular in the paranuclear
region) in up to 10% of positive cells; +2—marked
cytoplasmic (sometimes together with membranous) stain-
ing in 11–30% of the cells); +3—high expression (more than
30% of positive cells). Similarly, vimentin expression was
evaluatedin the entire slides bothin the areaof the tumor and
in the stroma, as follows: 0—no reactivity; +1—weak, when
observed any (also granular in paranuclear region) cytoplas-
mic staining pattern (in up to 10% of positive cells); +2—
marked cytoplasmic (sometimes together with membranous)
staining in 11–30% of the cells); +3—high expression (more
than 30% of positive cells). Variable scales were used to
evaluate an amount of the cells semi-quantitatively, depend-
ing on their general number in the specimen, an average cell
number per 1hpf (high power field, objective magnification
x40). CD56+ and CD57+ cells were thus estimated as
follows: 0—lack of positive cells; +1—single positive cells
in the specimen; +2—2–5 positive cells per 1hpf; +3—more
than 5 positive cells/1hpf.
Statistical Analysis
The distribution of variables in the study groups of the
patients checked with the use of the Shapiro-Wilk test
showed that each of the patients was in fact different
from normal. The statistical significance between the
groups was determined by the Kruskal-Wallis test, one-
way analysis of variance by ranks. The Mann–Whitney
U test was then used as applicable. All statistical analyses
were carried out with the Statistica 8.0 software program.
A p value <0.05 was considered indicative of statistical
significance.
Results
The Immunoreactivity of Antigens in Adenocarcinomas
and Their Stroma
The Analysis of CD56 and CD57 Immunoreactivity
in the Tissue Slides Examined
CD56 antigen immunoreactivity was found in 14.2% of the
adenocarcinoma samples and in 8% of the stromal samples
(Fig. 1a). CD57 antigen immunoreactivity was demonstrated
in 40% of the adenocarcinoma tissue slides and in 11.4% of
Fig. 2 MT antigen immunoreactivity in adenocarcinoma and stromal
tissue slides. The MT immunoreactivity in adenocarcinoma represents
the nuclear-cytoplasmic pattern of staining. Moderately differentiated
adenocarcinoma; sample magnification 20x
Fig. 3 MT antigen immunoreactivity in stromal fibroblasts marked
with stars representing the membranous-cytoplasmic pattern of
staining. Moderately differentiated adenocarcinoma; sample magnifi-
cation 40x
Fig. 4 Vimentin antigen immunoreactivity in adenocarcinoma and
stromal tissue slides representing the membranous-cytoplasmic stain-
ing pattern. Tumor nests are almost vimentin negative (stars) while in
the tumor microenvironment vimentin immunoreactivity is very strong
and is represented by fibroblasts. Moderately differentiated adenocar-
cinoma; sample magnification 40×
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expression (Fig. 1b).
The Analysis of MT Immunoreactivity in the Tissue Slides
Examined
MT antigen immunoreactivity was demonstrated in 68.5%
of the adenocarcinoma tissue slides and most frequently
exhibited the nuclear-cytoplasmic pattern of staining. The
strongest MT immunoreactivity was observed in the
marginal areas of the tumor nest, while in the center of
the nest MT immunoreactivity was weaker (Fig. 2). MT
immunoreactivity was also observed in 20% of the stromal
tissue slides (Fig. 3) and represented the membranous-
cytoplasmic pattern of staining. This same immunoreactiv-
ity was also observed on stromal fibroblasts (Fig. 3).
The Analysis of Vimentin Immunoreactivity in the Tissue
Slides Examined
Vimentin antigen immunoreactivity was demonstrated in
45.7% of the adenocarcinoma tissue slides and in 54.2% of
the stromal tissue slides. The stromal fibroblasts strongly
expressed vimentin and exhibited the membranous-
cytoplasmic pattern of expression (Figs. 4 and 5). Vimentin
immunoreactivity was not observed in the epithelia of the
palatine tonsils.
The Comparison of the Immunoreactivity Levels
of the Antigens Analyzed in Adenocarcinoma
and Their Stromas
The results obtained for the immunoreactivity of the
antigens analyzed in the tissue samples of adenocarcinomas
and their stromas are presented in Table 3.
A statistically significantly higher number of CD57-
expressing cells were identified in the adenocarcinoma
tissue slides than in the stromal slides. Also, a statisti-
cally significantly higher level of MT immunoreactivity
was observed in the adenocarcinoma tissue slides than in
the stromal slides. In turn, a statistically significantly
higher vimentin immunoreactivity level was identified in
the tumor microenvironment than in the tumor tissue
slides.
The Comparison of Antigen Immunoreactivity Levels
in the Adenocarcinoma and Reference Group Tissue Slides
The results obtained are presented in Table 4.
A statistically significantly higher number of CD56- and
CD57-expressing cells were identified in the reference
tissue slides than in the adenocarcinoma slides. In turn, a
statistically significantly higher MT immunoreactivity level
was identified in the adenocarcinoma tissue slides than in
the reference tissue slides. There were no differences
between the adenocarcinoma tissue slides and the reference
slides as far as vimentin immunoreactivity.
The Comparison of the Levels of Antigen Immunoreactivity
in the Stroma and Reference Group Tissues
The results obtained are presented in Table 5.
A statistically significantly higher number of CD56- and
CD57-expressing cells were identified in the reference tissue
slides than in the stromal slides. In turn, a statistically
significantly higher level of vimentin immunoreactivity was
identifiedinthetumormicroenvironmentthaninthereference
slides. There were no differences between the stroma and
reference tissue slides as far as MT immunoreactivity
Fig. 5 Vimentin antigen immunoreactivity in adenocarcinoma and
stromal tissue slides representing the membranous-cytoplasmic stain-
ing pattern. Tumor nests are almost vimentin negative (stars) while in
the tumor microenvironment vimentin immunoreactivity is very strong
and is represented by fibroblasts. Moderately differentiated adenocar-
cinoma; sample magnification 40×
Antigen Adenocarcinoma Median (IQR) Stroma Median (IQR) p value
CD56 0 (0) 0 (0) NS
CD57 0 (2) 0 (0) 0.01
MT 2 (3) 0 (0) 0.0002
Vimentin 0 (0) 3 (1) 0.004
Table 3 The comparison of the
immunoreactivity levels of the
analyzed antigens in adenocar-
cinoma and the stroma
IQR the interquartile range; NS
non statistically significant;
110 M. Dutsch-Wicherek et al.The analysis of antigen immunoreactivity with respect to
tumor grade and size and the presence of lymph node
metastases did not reveal any significant differences.
Discussion
In our present study the microenvironment of the adeno-
carcinoma was typified by the immunoreactivity of both
vimentin and MT.
The remodeling of the tumor microenvironment would
seem to involve the whole of the tissue adjacent to the
tumor—the cells, the extracellular matrix, and the pattern of
expressed proteins. The mesenchymal phenotype acquired
by the tumor enables its local growth and dissemination and
is typified by the expression of mesenchymal proteins such
as vimentin [9, 10]. In the present study we observed that
the level of vimentin immunoreactivity was significantly
higher in the tumor stroma than in either the tumor itself or
the reference samples. This might be a consequence of the
mesenchymal phenotype acquired by the tumor microenvi-
ronment as it seems to facilitate the progression of the
tumor and the development of metastases. Additionally, we
observed that any vimentin immunoreactivity in the tumor
microenvironment was independent of the vimentin immu-
noreactivity found in the tumor itself. For example, there
were tumors that did not express vimentin while their
microenvironments did. Moreover, vimentin in the tumor
microenvironment was expressed by the fibroblasts; this
suggests that these fibroblasts represent carcinoma-
associated fibroblasts, especially as vimentin is one of the
markers used for the identification of these cells [18].
Overall, these findings suggest that the presence of
vimentin immunoreactivity in the microenvironment of
salivary gland adenocarcinoma could be an important
marker of a remodeled microenvironment.
Next, we observed that metallothionein was expressed
by both the tumor and the tumor stroma. The level was
significantly higher in the tumor samples than in the
stromal tissue samples, and significantly higher again in
the tumor samples than in the reference samples. MT
expression has been observed in various malignant
tumors [22]. Within tumor nests MT has been mainly
located in the peripheral part of tumor nests in cases of
oral cavity squamous cell carcinoma. Such tumor cells
were typified by a higher proliferative and lower
apoptosis rate than the tumor cells located in the center
of the nest [27, 33]. Meanwhile, in nasopharyngeal cancer
a negative correlation has been found between the MT
expression and the rate of tumor cells undergoing
apoptosis [33, 34]. Similarly, in head and neck squamous
cell carcinoma, MT expression was found to be stronger in
the peripheral portion of the tumor nests and its presence
was identified in the adjacent stroma [24]. The type of MT
immunoreactivity in the salivary gland adenocarcinoma in
the present study was similar to the type of expression
found in other tumors: it was the strongest in the
peripheral parts of the tumor and weakest in the center
of the tumor nests.
MT expression has also been observed in healthy tissues,
such as in the basal part of normal epithelium in the oral
cavity and nasopharynx. Its presence would seem to be
linked to its pro-proliferative activity since this part of the
epithelium is composed of the proliferating cells responsi-
ble for its renewal [27, 33, 34].
The presence of MT immunoreactivity in the stroma is
an interesting phenomenon in itself. It has been demon-
strated that MT can be expressed by healthy tissue in the
tumor vicinity and its expression has been related to the
presence of metastases in head and neck squamous cell
carcinoma and in breast adenocarcinoma [24, 35]. MT
expression in the tumor stroma has been speculated to result
Antigen Adenocarcinoma Median (IQR) Reference group Median (IQR) p value
CD56 0 (0) 1.5 (2) p=0.01
CD57 0 (2) 2.4 (3) p=0.01
MT 2 (3) 0.1 (0) P=0.001
Vimentin 0 (0) 0 (0) NS
Table 4 The comparison of the
immunoreactivity levels of the
analyzed antigens in the adeno-
carcinoma and the reference
group
IQR the interquartile range; NS
non statistically significant
Antigen Stroma Median (IQR) Reference group Median (IQR) P value
CD56 0 (0) 1.5 (2) p=0.01
CD57 0 (0) 2.4 (3) p=0.001
MT 0 (0) 0.1 (0) NS
Vimentin 3 (1) 0 (0) p=0.001
Table 5 The comparison of the
immunoreactivity levels of the
analyzed antigens in the stroma
and the reference group
IQR the interquartile range; NS
non statistically significant
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sis [24, 35]. In the present study we did not observe any
significant relationship between the MT immunoreactivity
and the presence of metastases. Interestingly, however, MT
immunoreactivity in the tumor microenvironment was
exhibited by stromal fibroblasts. Since these fibroblasts
strongly expressed vimentin it would seem likely that they
were cancer-associated fibroblasts [18] which are responsi-
ble for the modification of the tumor microenvironment as
well as for determining tumor growth. The presence of
cross-talk between the tumor cells and the stromal
fibroblasts was confirmed in the co-cultured model of
breast cancer. Additionally, it was shown that the fibro-
blasts from the tumor-stromal interface were the most active
and were able to induce EMT and vimentin expression in a
breast cancer model [36].
As MT expression protects the cell against apoptosis and
promotes its proliferation, it would seem to be a marker of
microenvironment remodeling. Moreover, MT- positive
fibroblasts—that is, cancer-associated fibroblasts—would
seem to form an integral part of the remodeled tumor
microenvironment and also to condition tumor growth.
E. Canpolat et al. have postulated an important role for
MT in immunomodulation. Since MT inhibits the immune
response, it most likely helps to suppress the anticancer
response [37]. In the light of MT’s immunomodulating role,
the presence of MT immunoreactivity in the tumor
microenvironment may indicate that it is involved in
creating the suppressive microenvironment.
The number of CD56- and CD57-expressing cells
identified in both the adenocarcinoma and stroma tissue
slides was significantly lower than in the reference group.
There were no differences, however, in the number of
CD56-expressing cells in the adenocarcinoma tissue slides
in comparison to the stroma slides. In turn, a significantly
higher number of CD57-expressing cells were identified in
the adenocarcinoma than in the stroma tissue slides.
The level of anticancer response in the performed study,
realized by CD56-expressing lymphocytes, seemed to
remain at a comparable level in the tumor and its stroma,
although the number of CD57-expressing lymphocytes was
found to be higher in the tumor than in the stroma.
Moreover, the number of effector cells in the tumor and
its stroma remained significantly lower than in the control
group; this indicated a deficit of these cells in the tumor and
its microenvironment. Indeed, a decreased number of
tumor-infiltrating lymphocytes in malignant tumors has
been demonstrated in various neoplasms and correlated
with tumor aggressiveness and poor prognosis [38, 39]. It
has also been determined that the function of TIL in
malignant tumors is disturbed and that the decreased
number of lymphocytes is accompanied by the alteration
of their activity [40]. In gastric and colon cancers, the
number of T CD56-expressing and T CD57-expressing
lymphocytes was enhanced in the peripheral blood and in
among the TIL [28, 29]. Additionally, the homeostasis
between Th1/Th2 responses plays a key role in various
types of immune responses, including the anticancer
response [41]. The Th1 response has been shown in vivo
in various malignant neoplasms to be fundamental in
inducing a strong anticancer response [42]. In fact, in
patients with advanced malignant tumors, the Th1 response
is inhibited, while the Th2 response dominates [43].
In conclusion, the stroma of salivary gland adenocarci-
noma is characterized by remodeling. The remodeling is
represented by the expression of both vimentin and MT and
by a deficit in CD57- and CD58-expressing cell infiltration.
This situation would seem to be the result of immune
tolerance for the tumor developing within the tumor
microenvironment. Finally, the presence of MT and
vimentin immunoreactivity in the fibroblasts of the tumor
stroma may constitute a marker of active tissue remodeling.
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